10 Small-Cap Stocks to Buy According to David Einhorn’s Greenlight Capital
In this article, we discuss the top 10 small-cap stocks to buy according to David Einhorn's Greenlight Capital.
Neubase Therapeutics Inc. (NBSE)
Get Email AlertsSector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Greenlight Capital David Einhorn | 2,727,027 | $5,127 | 0.32% | |
| 2. | Point72 Asset Management Steve Cohen | 1,250,000 | $2,350 | 0% | |
| 3. | AIGH Investment Partners Orin Hirschman | 1,027,585 | $1,932 | +3% | 0.47% |
| 4. | Sio Capital Michael Castor | 906,445 | $1,704 | 0.56% | |
| 5. | Springbok Capital Gavin Saitowitz And Cisco J. Del Valle | 311,000 | $585 | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.92 | 6,200 | Officer | 11,200 | 2022-03-30 | Filing | |
| $1.81 | 10,000 | Officer | 30,000 | 2022-03-18 | Filing | |
| $1.74 | 10,000 | Officer | 20,000 | 2022-03-17 | Filing | |
| $1.62 | 10,000 | Officer | 10,000 | 2022-03-16 | Filing | |
| $1.62 | 1,000 | Director | 44,960 | 2022-03-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 1,059,054 | $1,991 | 0% | |
| 2. | 1,000,000 | $1,880 | 0.57% | |
| 3. | 939,412 | $1,766 | 0.73% | |
| 4. | 634,618 | $1,193 | 0.01% | |
| 5. | 426,424 | $802 | 0.48% |
News See All
NeuBase Therapeutics, Inc. (NBSE): A Bull Case Thesis
We came across a bullish thesis on NeuBase Therapeutics, Inc. (NBSE) on ValueInvestorsClub by savvystockguy. Previously David Einhorn talked about this stock in his fund's annual letter.
Is Neubase Therapeutics (NBSE) Stock a Buy For 2021?
Greenlight Capital Fund recently released its Q4 2020 Investor Letter, a copy of which you can download here.
Here is What Hedge Funds Think About NeuBase Therapeutics, Inc. (NBSE)
In this article we will check out the progression of hedge fund sentiment towards NeuBase Therapeutics, Inc. (NASDAQ:NBSE) and determine whether it is a good investment right now.
Is NeuBase Therapeutics, Inc. (NBSE) A Good Stock To Buy?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first.
NeuBase Therapeutics, Inc. (NBSE): Hedge Funds Dropped The Ball?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Billionaire Hedge Funds
